ChoiceBroking‬ ‪‎Financial‬ Tips Morning Tea: ‪‎Buy‬ ‪‎PNBBANK‬ @137.50-139 ‪‎TGT142‬ ‪‎SL‬ 136 Buy ‪AUROPHARMA‬ @843-848 ‪TGT‬ 865 SL 834

1. SEBI Certified – Research Analyst www.choiceindia.com
Global View
India Update
Today’s Event/ Stock in News
PNBHousingFinance,asubsidiaryofPunjabNationalBank(PNB),isreportedlyplanningtoraise$75millionfromInternationalFinanceCorporation
(IFC), a member of the World Bank Group. The investment will be done by subscription to a secured fixed/floating rate non-covertible debenture
(NCD) issued by the company. These funds willbe used tofinance construction of green residentialbuildingsthatare certifiedbyrecognized green
building certification standards, including EDGE. The bank has reported 7.94% rise in its net profit at Rs 621.03 crore for the quarter ended
September 30, 2015 as compared toRs 575.34 crore for thesamequarterinthe previousyear.Thebank's totalincome hasincreasedby 5.23% to
Rs13701.93 croreforthequarterunderreviewfromRs13020.46 croreforthecorrespondingquarterofthepreviousyear.
Technical Outlook : Recently, the stock has given breakout of its symmetrical triangle formation at 137 levels on daily chart. Moreover stock has
been trading above 60 DEMA, which indicates that medium term trend remains up. A momentum indicator RSI reading is above 50 marks with
positive crossover, which point out for positive breath in the stock. So for trading perspective, one could Buy in the range of 137.50-139 for the
Targetof142 withtheSLof136.
PNB
AUROPHARMA
SEBI Registered – Research Analyst www.choiceindia.com * Please Refer Disclaimer on Website
Morning Tea
24th Nov 2015
Buy in the range of 843-848 for the Target of 865 with the SL of 834
Buy in the range of 137.50-139 for the Target of 142 with the SL of 136
AurobindoPharma has received finalapproval from the US Food &Drug Administration (USFDA) tomanufacture and market Sildenafil Tablets, 20
mg. This product is expected to be launched by Q4FY 2015-16. The approved ANDA is bioequivalent and therapeutically equivalent to the
referencelisteddrugproduct(RLD)REVATIO(sildenafilcitrate)Tablets20mgofPfizer,Inc.SildenafilTabletsareusedinthetreatmentofpulmonary
arterial hypertension (high blood pressure in the lungs). The approved product has an estimated market size of $80 million for the twelve months
ending September 2015. This is the 51st ANDA to be approved out of Unit VII formulation facility in Hyderabad, India for manufacturing Oral Non-
Antibiotic products. The pharmamajor now has a total of 219 ANDA approvals(190 Finalapprovalsincluding 10 from Aurolife Pharma LLC and 29
Tentativeapprovals)fromUSFDA.
Technical Outlook : On hourly chart, the stock has taken support of its rising trend line at 812 levels. Moreover, stock has been trading above 60
EMAonhourly chart, which suggest that short term trend isup.Amomentum indicatorRSI has moved above 60 levelson daily chart, whichpoint
outforpositivevolatilityinthestock.Sofortradingperspective,onecouldBuyintherangeof843-848 fortheTargetof865withtheSLof834.
Asian shares dragged their feet on Tuesday after a healthcare mega-merger failed to impress investors while the dollar held firm near an eight-
month high as investors grew more convinced of a US rate hike next month. Shanghai Composite index traded at -1.08 to 3571.91, Hang Seng
index traded at -0.69 % to 22511.45, Japan's benchmark Nikkei 225 index traded at -0.08% to 19863.51, South Korea's Kospi index traded up by
0.16%to2006.94 levels.TheSGXNiftysuggestsaflattonegativeopeningforourmarketsasitistradingat7819, downby32.50points.
USstockindexesclosedslightlylowerinaquiettradingdayonWallStreetafterlastweek'sstronggains,whileabighealthcaredealfailedtoimpress
investors on Monday. Pfizer's announcement of what is expected to be the biggest-ever healthcare deal pushed its shares down 2.6 percent
makingitoneofthebiggestdragsontheS&P.TargetcompanyAllerganclosed3.4-percentloweraftertheUSD160billiondealannouncement.The
Dow Jones industrial average fell 31.13 points, or 0.17 percent, to 17,792.68, the S&P 500 lost 2.58 points, or 0.12 percent, to 2,086.59 and the
NasdaqCompositedropped2.44points,or0.05percent,to5,102.48.

2. SEBI Certified – Research Analyst www.choiceindia.com
Bulk Deal
Corporate Action / Result Calendar
SEBI Certified – Research Analyst www.choiceindia.com
Morning Tea
Corporate Action:
Manappuram Finance Limited; Interim Dividend-Re 0.45/- Per Share
Result Calendar:
STARLIT
24th Nov 2015
Security in Ban
SEBI Registered – Research Analyst www.choiceindia.com * Please Refer Disclaimer on Website
Sr.No Deal Date Security Name Client Name Deal Type Quantity Price
1 23/11/2015 SPECIAPP ANVITA REAL ESTATE PRIVATE LIMITED B 1407009 1.03
2 23/11/2015 SPECIAPP ABJAYONI TRADING PRIVATE LIMITED S 1405800 1.03
3 23/11/2015 LOVABLE NALANDA INDIA EQUITY FUND LIMITED S 800000 205.28
4 23/11/2015 CMAHENDRA SASHWAT COMMODITIES PVT. LTD. B 700000 1.29
5 23/11/2015 LOVABLE Reliance Capital Trustee Co Ltd A/c MF B 674305 205.00
6 23/11/2015 KYRALANDS INVENTURE GROWTH & SECURITIES LTD. B 652676 0.51
7 23/11/2015 BLISSGVS SHRUTI VISHAL RAO S 646000 175.02
8 23/11/2015 KYRALANDS INVENTURE GROWTH & SECURITIES LTD. S 601167 0.51
DLF, IBREALEST and JINDALSTEL

3. SEBI Certified – Research Analyst www.choiceindia.com
Contact Us
www.choiceindia.com
www.choiceindia.comcustomercare@choiceindia.com
Disclaimer
This is solely for information of clients of Choice Broking and does not construe to be an investment advice. It is also not intended as an offer or solicitation for the purchase and sale of any financial
instruments. Any action taken by you on the basis of the information contained herein is your responsibility alone and Choice Broking its subsidiaries or its employees or associates will not be liable in
any manner for the consequences of such action taken by you. We have exercised due diligence in checking the correctness and authenticity of the information contained in this recommendation, but
Choice Broking or any of its subsidiaries or associates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the
information contained in this recommendation or any action taken on basis of this information. Technical analysis studies market psychology, price patterns and volume levels. It is used to forecast
future price and market movements. Technical analysis is complementary to fundamental analysis and news sources. The recommendations issued herewith might be contrary to recommendations
issued by Choice Broking in the company research undertaken as the recommendations stated in this report is derived purely from technical analysis. Choice Broking has based this document on
information obtained from sources it believes to be reliable but which it has not independently verified; Choice Broking makes no guarantee, representation or warranty and accepts no responsibility
or liability as to its accuracy or completeness. The opinions contained within the report are based upon publicly available information at the time of publication and are subject to change without
notice. The information and any disclosures provided herein are in summary form and have been prepared for informational purposes. The recommendations and suggested price levels are intended
purely for trading purposes. The recommendations are valid for the day of the report however trading trends and volumes might vary substantially on an intraday basis and the recommendations may
be subject to change. The information and any disclosures provided herein may be considered confidential. Any use, distribution, modification, copying, forwarding or disclosure by any person is
strictly prohibited. The information and any disclosures provided herein do not constitute a solicitation or offer to purchase or sell any security or other financial product or instrument. The current
performance may be unaudited. Past performance does not guarantee future returns. There can be no assurance that investments will achieve any targeted rates of return, and there is no guarantee
against the loss of your entire investment.
POTENTIAL CONFLICT OF INTEREST DISCLOSURE (as on date of report) Disclosure of interest statement – • Analyst interest of the stock /Instrument(s): - No. • Firm interest of the stock /
Instrument (s): - No.
SEBI Certified – Research Analyst www.choiceindia.com
Research Team
Mr. Sumeet Bagadia Associate Director
Kunal Parmar Research Associate
Amit Pathania Research Associate
Vikas Chaudhari Research Associate
Kapil Shah Research Associate
Rajnath Yadav Research Associate
Satish Kumar Research Associate
Morning Tea
24th Nov 2015
SEBI Registered – Research Analyst www.choiceindia.com * Please Refer Disclaimer on Website
Kunal Parmar
Digitally signed by Kunal Parmar
DN: cn=Kunal Parmar, o=Choice Equity
Broking Pvt Ltd., ou=Research Dept.,
email=kunal.parmar@choiceindia.com, c=IN
Date: 2015.11.24 08:47:08 +05'30'